pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated is a pharma organization headquartered in LA MESA, CA, IE. It trades on NYSE under ticker RGBP. Primary therapeutic focus areas include Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, C
LA MESA, CA, IE HQ
Public company Type
RGBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Autologous mononuclear cells
Phase 1 · mab · Congenital Heart Disease, SRV Dependent
Autologous mononuclear cells for Congenital Heart Disease, SRV Dependent is a Phase 1 program (mab) at Regeneron Ireland Designated Activity Company (DAC) with 1 ClinicalTrials.gov record(s).
Internal code 21-000088
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron Ireland Designated Activity Company (DAC)
- Phase
- Phase 1
- Modality
- mab
- Indication
- Congenital Heart Disease, SRV Dependent
- Status
- active
- Trials
- 1